Diabetes Care 23: , 2000
|
|
- Charlotte Fields
- 7 years ago
- Views:
Transcription
1 Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes MARCO PAHOR, MD BRUCE M. PSATY, MD, PHD MICHAEL H. ALDERMAN, MD WILLIAM B. APPLEGATE, MD, MPH JEFF D. WILLIAMSON, MD, MHS CURT D. FURBERG, MD, PHD OBJECTIVE To assess whether ACE inhibitors are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes. RESEARCH DESIGN AND METHODS This study is a review and meta-analysis of randomized controlled trials that included patients with type 2 diabetes and hypertension who were randomized to an ACE inhibitor or an alternative drug, were followed for 2 years, and had adjudicated cardiovascular events. RESULTS A total of 4 trials were eligible. The Appropriate Blood Pressure Control in Diabetes (ABCD) trial (n = 470) compared enalapril with nisoldipine, the Captopril Prevention Project (CAPPP) (n = 572) compared captopril with diuretics or -blockers, the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET) (n = 380) compared fosinopril with amlodipine, and the U.K. Prospective Diabetes Study (UKPDS) (n = 758) compared captopril with atenolol. The cumulative results of the first 3 trials showed a significant benefit of ACE inhibitors compared with alternative treatments on the outcomes of acute myocardial infarction (63% reduction, P 0.001), cardiovascular events (51% reduction, P 0.001), and allcause mortality (62% reduction, P = 0.010). These findings were not observed in the UKPDS. The ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials. None of the findings were explained by differences in blood pressure control. CONCLUSIONS Compared with the alternative agents tested, ACE inhibitors may provide a special advantage in addition to blood pressure control. The question of whether atenolol is equivalent to captopril remains open. Conclusive evidence on the comparative effects of antihypertensive treatments will come from large prospective randomized trials. Diabetes Care 23: , 2000 The primary goal of antihypertensive treatment is to prevent clinical complications and not simply to lower elevated blood pressure. Evidence from the Systolic Hypertension in the Elderly Program and the Systolic Hypertension in Europe Trial showed that, compared with placebo, treatment of hypertension in patients with type 2 diabetes prevents major clinical complications (1,2). Data from the From the Sticht Center on Aging (M.P., W.B.A., J.D.W.), Department of Internal Medicine, and the Department of Public Health Sciences (C.D.F.), Wake Forest University, Winston-Salem, North Carolina; the Cardiovascular Health Research Unit (B.M.P.), Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington; and the Department of Epidemiology and Social Medicine (M.H.A.), Albert Einstein College of Medicine, Bronx, New York. Address correspondence and reprint requests to Marco Pahor, MD, Sticht Center on Aging, Department of Internal Medicine, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston- Salem, NC mpahor@wfubmc.edu. Received for publication 21 October 1999 and accepted in revised form 1 February Abbreviations: ABCD, Appropriate Blood Pressure Control in Diabetes; CAPPP, Captopril Prevention Project; FACET, Fosinopril Versus Amlodipine Cardiovascular Events Trial; HOPE, Heart Outcomes Prevention Evaluation; RR, relative risk; UKPDS, U.K. Prospective Diabetes Study. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Hypertension Optimal Treatment trial and the U.K. Prospective Diabetes Study (UKPDS) suggest that, in patients with diabetes, greater blood pressure reduction results in greater clinical benefits (3,4). Although these studies document that treatment of high blood pressure is beneficial in hypertensive patients with type 2 diabetes, none of these trials provides information on the relative therapeutic benefit of individual antihypertensive agents. Recent comparative trials and observational studies in diabetes have suggested that, for the prevention of cardiovascular events, ACE inhibitors may be superior to alternative antihypertensive agents (5,6). That the greater benefit of ACE inhibitors was not explained by better blood pressure control indicates that other mechanisms linked to ACE inhibition may have played an additional role in the prevention of major clinical events. The purpose of the present review and meta-analysis is to summarize the current evidence from randomized clinical trials with clinical outcomes that directly compared ACE inhibitors to alternative antihypertensive agents in patients with hypertension and type 2 diabetes. RESEARCH DESIGN AND METHODS To be included in the meta-analysis, a study had to be a randomized controlled trial published in a peerreviewed journal that included patients with type 2 diabetes and hypertension, evaluated an ACE inhibitor versus an active treatment, followed the participants for 2 years to allow the occurrence of a sufficient number of clinical events, and used predefined criteria to adjudicate the cardiovascular events. Studies were identified through PubMed searches using the following key words: ACE inhibitors, diabetes, hypertension, and clinical trial. The searches were extended through January Letters to the editor, commentaries, review articles, editorials, and observational studies were not included. Bibliographies of the retrieved articles were searched to identify other eligible studies, and information from colleagues was used to identify more recently published articles. 888 DIABETES CARE, VOLUME 23, NUMBER 7, JULY 2000
2 Pahor and Associates Table 1 Baseline characteristics according to treatment Age Men BMI Macroalbuminuria Duration of Systolic blood Diastolic blood Trial Agent n (years) (%) (kg/m 2 ) (%) diabetes (years) pressure (mmhg) pressure (mmhg) ABCD (7) Enalapril ± ± ± ± ± 7 Nisoldipine ± ± ± ± ± 7 CAPPP (8) Captopril ± ± ± 10 Diuretic/ -blockers ± ± ± 10 FACET (9) Fosinopril ± ± ± ± ± 10 Amlodipine ± ± ± ± ± 8 UKPDS (10) Captopril ± ± ± ± 10 Atenolol ± ± ± ± 10 Data are means ± SEM, unless otherwise indicated. The following elements were abstracted: design, sample size, randomized treatments, follow-up time, average age, sex distribution, average BMI, proportion of participants with macroalbuminuria, duration of diabetes, baseline systolic and diastolic arterial pressures, and the number of events (including acute myocardial infarction, stroke, combined cardiovascular events, and all-cause mortality) occurring in each treatment group. The initial search identified 195 articles. Of those, 4 trials met all of the inclusion criteria. Those trials were the Appropriate Blood Pressure Control in Diabetes (ABCD) trial (7), the diabetic group of the Captopril Prevention Project (CAPPP) (8), the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET) (9), and the UKPDS (Table 1) (10). The recently published Swedish Trial in Old Patients with Hypertension-2 compared the use of -blockers or diuretics with the use of ACE inhibitors or Ca antagonists and was not included because outcome data in the subgroup of patients with diabetes in that study were not published and were not available from the authors (B. Dalhof, personal communication) (11). For the combined outcome of cardiovascular events, we adopted the definition used in each trial. In the ABCD trial, the cardiovascular events included cardiovascular death, fatal and nonfatal acute myocardial infarction, congestive heart failure requiring hospitalization, fatal or nonfatal stroke, and pulmonary infarction. Because the number of events in patients with diabetes was not reported in the CAPPP, we estimated these numbers by using the sample size, the relative risk (RR) (95% CI), and the P value of the difference between the 2 treatment groups. In the CAPPP, the cardiovascular events included cardiovascular deaths, fatal and nonfatal acute myocardial infarction, and fatal or nonfatal stroke. In the FACET, the cardiovascular events included fatal and nonfatal acute myocardial infarction, fatal and nonfatal stroke, and angina requiring hospitalization. In the UKPDS, the combined end point of cardiovascular events was not reported. We calculated the total number of cardiovascular events by adding the number of fatal and nonfatal acute myocardial infarctions and strokes, the number of congestive heart failure events, and the number of sudden deaths. Because more than 1 event may have occurred in a single patient, this method is likely to have slightly overestimated the number of patients with cardiovascular events in the UKPDS. The overall relative risk (85% CI) of each outcome was calculated with Peto s method (12). Cochran s test for heterogeneity was used to assess the extent to which the differences among the trial results were because of random fluctuations (13). RESULTS In the 4 eligible trials (the ABCD trial, the CAPPP, the FACET, and the UKPDS), the total number of participants was 2,180 (1,133 randomized to an ACE inhibitor and 1,047 randomized to an alternative active agent) with a total follow-up experience of 13,300 personyears. The participants characteristics according to treatment are shown in Table 1. In the ABCD trial, the medication daily dose was mg for nisoldipine and 5 40 mg for enalapril. In the CAPPP, 50 mg captopril was given once or twice a day, and mg atenolol or metoprolol, 25 mg hydrochlorothiazide, or 2.5 mg bendrofluazide was given once a day. In the FACET, 20 mg fosinopril or 10 mg amlodipine was given once a day. In the UKPDS, the dose of captopril was mg twice a day, and the dose of atenolol was mg once a day. In the ABCD trial, the FACET, and the UKPDS, systolic (Fig. 1) and diastolic blood pressure decreased significantly with both treatments. In the ABCD trial and the UKPDS, no significant differences were evident in blood pressure control among the randomized treatment groups. In the FACET, the patients randomized to amlodipine achieved a significantly lower systolic blood pressure level than patients randomized to fosinopril. Data on blood pressure control in the diabetic patients of the CAPPP have not been reported. The number of events by treatment group in each trial is shown in Table 2, and the relative risks (95% CIs) of outcomes for ACE inhibitors versus other agents are depicted in Fig. 2. In the ACE inhibitor group, the risk of acute myocardial infarction was significantly decreased in the ABCD trial and the CAPPP, was nonsignificantly lower in the FACET, and was nonsignificantly higher in the UKPDS compared with the alternative treatment. For the outcome of stroke, no significant differences were evident among treatments in any of the trials. In the ACE inhibitor group, the risk of combined cardiovascular events was significantly decreased in the ABCD trial, the CAPPP, and the FACET, and was nonsignificantly increased in the UKPDS compared with the alternative treatment; the risk of all-cause mortality was significantly decreased in the CAPPP, was nonsignificantly lower in the ABCD trial and the FACET, and was nonsignificantly higher in the UKPDS. In initial analyses, the data of the 4 trials were combined. For ACE inhibitors versus other treatments, the RRs (95% CIs) of acute myocardial infarction, stroke, cardiovascular events, and all-cause mortality DIABETES CARE, VOLUME 23, NUMBER 7, JULY
3 Therapeutic benefits of ACE inhibitors Figure 1 Systolic blood pressure changes during follow-up according to treatment in the ABCD trial, the FACET, and the UKPDS. The data of the CAPPP have not been reported. were 0.73 ( ), 0.86 ( ), 0.77 ( ), and 0.85 ( ), respectively. To identify potential outliers, we tested the heterogeneity of the results of the trials for individual outcomes of interest through iterative analyses. The test for heterogeneity was significant for the outcomes of acute myocardial infarction and cardiovascular events when the data of the UKPDS were combined with the other 3 trials (P for both outcomes) but not when the UKPDS was excluded from the meta-analysis. Thus, only the data for the ABCD trial, the CAPPP, and the FACET were used in the formal meta-analytic calculations. When the data of the ABCD trial, the CAPPP, and the FACET were combined, the patients randomized to an ACE inhibitor had a significantly lower risk of acute myocardial infarction, cardiovascular events, and all-cause mortality than those randomized to an alternative treatment (P 0.001, P 0.001, and P = 0.010, respectively) (Fig. 2). Moreover, no heterogeneity was found with the reduced dataset. No such differences were evident for the outcome of stroke. CONCLUSIONS This review identified 4 trials in which patients with type 2 diabetes and hypertension were randomized to either an ACE inhibitor or to an alternative antihypertensive treatment and were followed for 2 years. The results of these trials have been previously reviewed (5), but to our knowledge, this is the first quantitative meta-analysis of their outcome data. The cumulative results of 3 trials (the ABCD trial, the CAPPP, and the FACET) showed a significant benefit of ACE inhibitors compared with alternative treatments on the outcomes of acute myocardial infarction (63% reduction, P 0.001), cardiovascular events (51% reduction, P 0.001), and all-cause mortality (62% reduction, P = 0.010). These findings were not observed in the UKPDS, which compared captopril with atenolol. The ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials. Why do the results of the UKPDS differ from those of the other trials? One possible explanation may be because of differences in population characteristics. In the UKPDS, diabetes was newly diagnosed compared with the other studies (Table 1). The duration of follow-up in the UKPDS is another difference from the other trials. Another explanation is the selective dropout from the trial. Patients randomized to atenolol were more likely to drop out of the randomized treatment (10), and they possibly received an ACE inhibitor if they had a compelling indication such as albuminuria or left ventricular dysfunction. The net effect of such a selective dropout would be to diminish any differences between atenolol and captopril. The potential frequent crossover between groups renders many aspects of the UKPDS difficult to interpret (14). Another plausible hypothesis is that the selective -blocker atenolol is equivalent to captopril. Recent reports indicate in both normotensive and hypertensive individuals that the suppression of angiotensin II levels achieved with -blockade is similar to that obtained with an ACE inhibitor (15). To confirm the hypothesis of equivalence of captopril and atenolol, one must assess the relative risk of events in the CAPPP by using diuretics and individual -blockers. The divergent effects found in the UKPDS compared with the other 3 trials indicate that the overall evidence of the comparative effects of ACE inhibitors is not yet conclusive. If ACE inhibitors are truly more beneficial than other agents for the treatment of hypertension in patients with diabetes, then what are the potential mechanisms? Blood pressure control did not differ significantly between treatments in the ABCD trial. In the FACET, the amlodipine group achieved a significantly lower systolic blood pressure level than the ACE inhibitor group. Total cholesterol levels were similar in both treatment groups in the ABCD trial and the FACET. Microal- Table 2 Number of clinical events according to treatment Mean follow-up ACE inhibitors Other therapies Trial (years) Agent n AMI Stroke CV Death Agent n AMI Stroke CV Death ABCD (7) 5 Enalapril Nisoldipine CAPPP (8) 6.1 Captopril Diuretic/ -blocker FACET (9) 2.8 Fosinopril Amlodipine UKPDS (10) 8.4 Captopril Atenolol Data are n. AMI, acute myocardial infarction; CV, cardiovascular events. 890 DIABETES CARE, VOLUME 23, NUMBER 7, JULY 2000
4 Pahor and Associates Acknowledgments The results of this study were presented at the 59th Annual Meeting of the American Diabetes Association, San Diego, CA, 19 June Figure 2 RR (95% CI) of outcomes for ACE inhibitors compared with other agents in the ABCD trial, the CAPPP, the FACET, the UKPDS, and in combined analyses. buminuria and serum creatinine levels during follow-up were similar in both treatment groups in the FACET. Metabolic control is another important factor that may affect cardiovascular outcomes. In the ABCD trial, the participants had poor metabolic control at baseline and during the 5 years of follow-up, but metabolic control was not significantly different between the ACE inhibitor and the Ca antagonist treated group. In the FACET, the patients randomized to the ACE inhibitor or the Ca antagonist achieved similar HbA 1c and fasting glucose levels during follow-up. Changes in blood pressure, metabolic control, or other risk factors during follow-up were not reported for diabetic patients enrolled in the CAPPP. Thus, from the published data, differences in blood pressure control, metabolic control, or other measured risk factors likely explain the substantial difference in major cardiovascular events. Several other mechanisms not measured in the reviewed trials may account for a greater therapeutic benefit of ACE inhibitors. ACE inhibitors may reduce cardiovascular risk by improving endothelial dysfunction (16), by reducing inflammation (17), and by promoting fibrinolysis through inhibition of plasminogen activator inhibitor 1 (18,19). The recently published Heart Outcomes Prevention Evaluation (HOPE) trial showed that the reduction in cardiovascular events with an ACE inhibitor was much greater than that expected from blood pressure reduction alone compared with placebo, which supports the view that additional mechanisms contribute to the prevention of cardiovascular events with ACE inhibition (20). The main findings of the HOPE trial were confirmed in patients with and without diabetes. The HOPE trial was not included in the present meta-analysis because the comparison group was treated with a placebo and not with an active agent as required by the inclusion criteria. In summary, blood pressure reduction per se is necessary to prevent clinical complications in hypertensive patients (21), but additional clinical benefits can be achieved by non blood pressure mechanisms. The evidence from the present review and meta-analysis of comparative trials in patients with hypertension and diabetes should not be considered conclusive. The available data support the view that, compared with the alternative agents tested, ACE inhibitors appear to provide a special advantage in addition to blood pressure control. The question of whether atenolol is equivalent to captopril remains open. Based on available data from comparative trials, using ACE inhibitors may be prudent as a first-line agent for the treatment of hypertension in patients with type 2 diabetes. Conclusive evidence on the comparative effects of antihypertensive treatments will come from large prospective randomized trials such as the Antihypertensive and Lipid Lowering Treatment To Prevent Heart Attack Trial (22). References 1. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276: , Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, Staessen JA: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340: , Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 351: , Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: , Pahor M, Psaty BM, Furberg CD: Treatment of hypertensive patients with diabetes. Lancet 351: , Pahor M, Psaty BM, Furberg CD: New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol 32 (Suppl. 2): S18 S23, Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: , Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: , Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial in patients with hypertension and NIDDM. DIABETES CARE, VOLUME 23, NUMBER 7, JULY
5 Therapeutic benefits of ACE inhibitors Diabetes Care 21: , Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317: , Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients With Hypertension-2 study. Lancet 354: , Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: , Cochran WG: Some methods for strengthening the common chi-square tests. Biometrics 10: , Nathan DM: Some answers, more controversy, from UKPDS: United Kingdom Prospective Diabetes Study. Lancet 352: , Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12: , Bridges AB, McLaren M, Belch JJ: A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients. Angiology 46: , Schindler R, Dinarello CA, Koch KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7: , Oshima S, Ogawa H, Mizuno Y, Yamashita S, Noda K, Saito T, Sumida H, Suefuji H, Kaikita K, Soejima H, Yasue H: The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 134: , Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation 96: , Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 324: , Joint National Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: , Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM: Rationale and design for the Antihypertensive and Lipid Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9: , DIABETES CARE, VOLUME 23, NUMBER 7, JULY 2000
Drug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
More informationHypertension Management in Patients With Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Hypertension Management in Patients With Diabetes The need for more aggressive therapy DAN R. BERLOWITZ, MD, MPH 1,2 ARLENE
More informationType 2 diabetes mellitus is a common disease with substantial
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Sandeep Vijan, MD, MS, and Rodney A. Hayward, MD Clinical Guidelines
More informationTreatment of Hypertension: JNC 8 and More
PL Detail-Document #300201 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Treatment of
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationAppropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Appropriate in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Robert W Schrier*, Raymond O Estacio, Philip S Mehler and William R Hiatt SUMMARY The hypertensive and
More informationHypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
More informationHYPERTENSION: Comparison of New Guidelines
HYPERTENSION: Comparison of New Guidelines L. Brian Cross, PharmD, BCACP, CDE Vice-Chair & Associate Professor Bill Gatton College of Pharmacy Department of Pharmacy Practice Associate Professor James
More informationNearly one in four adults
COVER ARTICLE Controlling Hypertension in Patients with Diabetes SHERRI L. KONZEM, PHARM.D., B.C.P.S. Memorial Family Practice Residency and University of Houston College of Pharmacy, Houston, Texas VICTORIA
More informationCase Study 6: Management of Hypertension
Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular
More informationBASED ON WORLD Health Organization
Treating High-Risk Diabetic Hypertensive Patients With Comorbid Conditions Robert W. Schrier, MD Diabetes mellitus, a highly prevalent metabolic and vascular disease, affects 155 million people worldwide.
More informationThe overall prevalence of hypertension in diabetic
Predictors of Blood Pressure Control in Patients With Diabetes and Hypertension Seen in Primary Care Clinics AJH 2005; 18:833 838 Diabetes Murali K. Duggirala, Robert M. Cuddihy, Maria-Teresa Cuddihy,
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationInitial Treatment of Hypertension
The new england journal of medicine clinical practice Initial Treatment of Hypertension Phyllis August, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem.
More informationPharmacologic Management of Hypertension in Patients with Diabetes
Pharmacologic Management of Hypertension in Patients with Diabetes KAREN L. WHALEN, PharmD, University of Florida College of Pharmacy St. Petersburg Campus, Seminole, Florida ROBERT D. STEWART, PharmD,
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More informationDrug Treatment for People with Hypertension
Treatment algorithm Drug treatment for essential HT Compelling indication / contraindication over choice of drug No Yes Go to Appendix 1 Start with either ACEI (or ARB if ACEI intolerant), calcium channel
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Diuretic-Based Treatment and Cardiovascular Events in Patients With Mild Renal Dysfunction Enrolled in the Systolic Hypertension in the Elderly Program Marco Pahor, MD; Ronald I.
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationC h a p t e r 4 4 Diabetes and Hypertension
C h a p t e r 4 4 Diabetes and Hypertension Harbir Kaur Rao 1, RS Gupta 1, AR Singh 1 Professor of Medicine, Government Medical College, Patiala, Punjab The person with diabetes who knows the most lives
More informationGuidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationElevated Blood Pressure Among U.S. Adults with Diabetes, 1988 1994
Elevated Blood Pressure Among U.S. Adults with Diabetes, 1988 1994 Linda S. Geiss, MA, Deborah B. Rolka, MS, Michael M. Engelgau, MD, MS Background: Methods: Results: Conclusions: Recent guidelines and
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationPapers. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Abstract. Introduction.
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials M R Law, N J Wald, J K Morris, R E Jordan Abstract Objective To determine the average reduction
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationNew in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001.
Focus on CME at McMaster University What s New in Diabetes By Sarah Capes, MD, FRCPC Presented at McMaster University, Hamilton, Ontario, October 2001. Diabetes is becoming more common. By the year 2025,
More informationHypertension is an extremely common
Reviews/Commentaries/Position T E C H N I C A L R E V I E W Statements The Treatment of Hypertension in Adult Patients With Diabetes CARLOS ARAUZ-PACHECO, MD 1 MARIAN A. PARROTT, MD, MPH 2 PHILIP RASKIN,
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationCarefully review the risks and potential, but unproven, benefits of treatment.
Hypertension This is a consensus guideline for the pharmacological management of hypertension with frailty. This information was developed by the Dalhousie University Academic Detailing Service and the
More informationPROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
More informationClinicians awareness and application
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Specialist Nurse Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT) A randomized controlled trial
More informationBlood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE
More informationJournal of Hypertension 2008, 26:2103 2111. a Department of Medicine, Karolinska University Hospital Solna, Stockholm,
Original article 2103 The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes Jan Östergren a, Neil R. Poulter b, Peter S. Sever b, Björn
More informationDRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationAssess adherence with medication and lifestyle changes at every opportunity and intervene if necessary
PPR thirty eight Prescribing Practice Review For Primary Care July 2007 Managing hypertension as a cardiovascular risk factor Key Messages Assess absolute cardiovascular risk and manage hypertension along
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationThe epidemiological studies have indicated that hypertension
The Impact of History of Hypertension and Type 2 Diabetes at Baseline on the Incidence of Stroke and Stroke Mortality Gang Hu, PhD; Cinzia Sarti, PhD; Pekka Jousilahti, PhD; Markku Peltonen, PhD; Qing
More informationCase study 28: Managing hypertension in diabetes
Case study 28: Managing hypertension in diabetes October 2003 An Independent, Australian organisation for Quality Use of Medicines National Prescribing Service Limited ACN 082 034 393 Level 7/418A Elizabeth
More informationDrug treatment of elevated blood pressure
Drug treatment of elevated blood pressure Mark Nelson, Professor and Chair, Discipline of General Practice Professorial Research Fellow, and Senior Member, Menzies Research Institute, University of Tasmania,
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationSpecial Communication
Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More informationHypertension management in diabetic patients
European Review for Medical and Pharmacological Sciences Hypertension management in diabetic patients Z. ANWER, P.K. SHARMA, V.K. GARG, N. KUMAR, A. KUMARI 2011; 15: 1256-1263 Department of Pharmaceutical
More informationRisk factors for peripheral artery disease
www.tasc-2-pad.org Risk factors for peripheral artery disease Based on the Inter-Society Consensus Edited by Dr Denis Clement University Hospital, Ghent, Belgium Supported by an educational grant from
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationThe incidence of cardiovascular disease (CVD)
Review Paper Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead Rigas Kalaitzidis, MD; George Bakris, MD The incidence of type 2 diabetes is increasing in the United
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationUse of antihypertensive medications in patients with diabetes in Ajman, UAE
Use of antihypertensive medications in patients with diabetes in Ajman, UAE Mohammed Arifulla 1*, Lisha J John 1, Jayadevan Sreedharan 2, Jayakumary Muttappallymyalil 2, Jenny Cheriathu 3, Sheikh Altaf
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationQuiz 5 Heart Failure scores (n=163)
Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the
More informationAfrican Americans & Cardiovascular Diseases
Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age
More informationThe approach to care of any patient with diabetes. Pharmacologic Management of the Patient with Newly Diagnosed Type 2 Diabetes
Pharmacologic Management of the Patient with Newly Diagnosed Type 2 Diabetes Case Study and Commentary, M. Angelyn Bethel, MD, and Mark N. Feinglos, MD, CM Abstract Objective: To review appropriate pharmacologic
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationManagement of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
More informationHeart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
More informationCombination Antihypertensive Therapy: When to use it Diabetes
Combination Antihypertensive Therapy: When to use it Diabetes George L. Bakris, MD, F.A.S.N., F.A.S.H. Professor of Medicine Director, ASH Comprehensive Hypertension Center The University of Chicago Medicine
More informationRetarding the Progression of Diabetic Nephropathy in Type 2 Diabetes Mellitus: Focus on Hypertension and Proteinuria
24 Review Article Retarding the Progression of Diabetic Nephropathy in Type 2 Diabetes Mellitus: Focus on Hypertension and Proteinuria GSL Lee, 1 MBBS, M Med (Int Med), FAMS (Renal Med) Abstract Introduction:
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationMicroalbuminuria: An increasingly recognized risk factor for CVD
Microalbuminuria: An increasingly recognized risk factor for CVD Long known to be associated with kidney disease, the importance of protein in the urine is now becoming recognized as a sensitive, accessible
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationAppendix: Description of the DIETRON model
Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationObserved Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy
1-36 Observed Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy Controlled Clinical Trials of Drug Treatment for Hypertension A Review Jeffrey A. Cutler, Stephen
More informationCorrespondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationCorporate Medical Policy Ambulatory Blood Pressure Monitoring
Corporate Medical Policy Ambulatory Blood Pressure Monitoring File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ambulatory_blood_pressure_monitoring 7/1982 4/2016 4/2017 4/2016 Description
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationIsabella Sudano & Franco Muggli
Swiss Hypertension Guidelines Isabella Sudano & Franco Muggli CoLaus, Swisshype ESC 2005 Dokumentenname Datum Seite 1 European Journal of Cardiovascular Prevention and Rehabilitation 2009 Guideline...
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationAntihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT
Antihypertensive Drug Management to Achieve Systolic Blood Pressure
More informationUse of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationDescription of problem Description of proposed amendment Justification for amendment ERG response
KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without
More informationCenters for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
March 7, 2014 Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Dear Sir or Madam: On behalf of the American Heart Association (AHA), including the American Stroke
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More information22 Treatment of Hypertension
Chapter 22 / Elderly Hypertensive Diabetics 451 22 Treatment of Hypertension in the Elderly Patient With Diabetes James R. Sowers, MD, FACE, FACP, FAHA and L. Michael Prisant, MD, FACC, FACP CONTENTS OVERVIEW
More informationThe Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis
Prevention and Rehabilitation The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis Paula T. Einhorn, MD, MS,
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More information